- Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category in almost 30 years.
- The company also highlighted completion of enrollment in other key clinical studies and recent substantial funding to support ongoing programs.
- The stock last closed at $107.14, with a 30 day return of 50.1% and a year to date return of 183.8%.
For investors watching NYSE:MANE, the strong move in the share price over the past month and year to date provides a clear backdrop for this clinical update. With a last close of $107.14, the stock has gained 50.1% over the past 30 days and 183.8% year to date, while the 7 day return is down 2.4%, reflecting some recent consolidation after a sharp run.
Looking ahead, the focus now shifts to how Veradermics translates these topline results, broader trial progress, and its recent funding into regulatory milestones and potential commercialization plans for VDPHL01. Investors are likely to monitor upcoming clinical readouts and any regulatory interactions closely, given the prospect of a first-in-decades oral treatment for pattern hair loss.
Stay updated on the most important news stories for Veradermics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Veradermics.
See which insiders are buying and buying and selling Veradermics following this latest news.
Investor Checklist
Quick Assessment
- ⚖️ Price vs Analyst Target: At US$107.14, Veradermics trades about 15% below the US$126 consensus target range midpoint.
- ✅ Simply Wall St Valuation: The stock is flagged as trading 71.7% below an estimated fair value, which is a wide discount.
- ✅ Recent Momentum: A 50.1% 30 day return shows very strong recent momentum into this Phase 2/3 topline readout.
There is only one way to know the right time to buy, sell or hold Veradermics. Head to Simply Wall St's company report for the latest analysis of Veradermics's Fair Value.
Key Considerations
- 📊 Positive Phase 2/3 topline data for VDPHL01 plus recent funding sharpen the story around a potential first in decades oral treatment for pattern hair loss.
- 📊 Watch upcoming regulatory updates, further trial readouts and how the share price behaves against the US$120 to US$138 analyst target range.
- ⚠️ The company currently reports no revenue and has had losses, and the share price has been highly volatile over the past three months.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Veradermics analysis. Alternatively, you can visit the community page for Veradermics to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com